Lyell VP sells 217 shares to cover taxes

Lyell Immunopharma, Inc. VP and Corporate Controller Veronica Sanchez Bulis reported a small open-market sale of company common stock.

Rhea-AI Filing Summary

Lyell Immunopharma, Inc. VP and Corporate Controller Veronica Sanchez Bulis reported a small open-market sale of company common stock. She sold 217 shares on May 11, 2026, automatically to cover a tax withholding obligation from the settlement of vested restricted stock units.

The shares were sold at a weighted average price between $18.91 and $19.30 per share. After this tax-related sale, she directly owns 15,420 shares of Lyell Immunopharma common stock.

Insider Trade Summary

Net Seller: 217 shares

Net Sell 1 txn

Insider Bulis Veronica Sanchez

Role VP, Corporate Controller

Sold 217 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	217	$18.91	$4K

Holdings After Transaction: Common Stock — 15,420 shares (Direct)

Footnotes (2)

1. F1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
2. F2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Key Figures

Shares sold: 217 shares Sale price range: $18.91–$19.30 per share Shares held after transaction: 15,420 shares +1 more

4 metrics

Shares sold 217 shares Open-market sale on May 11, 2026

Sale price range $18.91–$19.30 per share Weighted average price range for the sale

Shares held after transaction 15,420 shares Direct ownership following sale

Net shares sold 217 shares Net-sell direction in transaction summary

Key Terms

restricted stock units, weighted average price, open-market sale, tax withholding obligation

4 terms

restricted stock units financial

"from settlement of vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported above reflects the weighted average price of the shares"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax withholding obligation financial

"Shares automatically sold to cover tax withholding obligation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lyell Immunopharma (LYEL) report for Veronica Sanchez Bulis?

Lyell Immunopharma reported that VP and Corporate Controller Veronica Sanchez Bulis sold 217 common shares. The transaction occurred on May 11, 2026, and was an automatic sale to satisfy tax withholding obligations from the settlement of vested restricted stock units.

How many Lyell Immunopharma (LYEL) shares did the executive sell and at what price?

Veronica Sanchez Bulis sold 217 shares of Lyell Immunopharma common stock. The weighted average sale price ranged from $18.91 to $19.30 per share, reflecting multiple executions within that price band during the same trading session.

Why were Veronica Sanchez Bulis’s Lyell Immunopharma (LYEL) shares sold?

The 217 shares were automatically sold to cover a tax withholding obligation. This obligation arose from the settlement of vested restricted stock units, meaning the sale was a compensation-related, tax-driven event rather than a discretionary portfolio decision.

How many Lyell Immunopharma (LYEL) shares does the executive hold after the Form 4 transaction?

Following the reported transaction, Veronica Sanchez Bulis directly holds 15,420 shares of Lyell Immunopharma common stock. This figure reflects her position after the 217-share sale executed to address tax withholding on vested restricted stock units.

What type of transaction was reported in the Lyell Immunopharma (LYEL) Form 4?

The filing shows a non-derivative open-market sale of common stock by Veronica Sanchez Bulis. Although coded as a sale, footnotes clarify it was an automatic transaction to cover tax withholding from vested restricted stock units, not an ordinary discretionary stock sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 06:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bulis Veronica Sanchez

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY, SUITE 101

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Corporate Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S		217(1)	D	$18.91(2)	15,420	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	/s/ Mark Meltz, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)